{
    "clinical_study": {
        "@rank": "72337", 
        "acronym": "TAB-R", 
        "brief_summary": {
            "textblock": "This registry is designed to monitor the real world clinical performance and safety of the\n      V8 device used to perform balloon aortic valvuloplasty (BAV). Additional analyses or\n      calculations may be obtained from the imaging or evaluations already performed per the\n      sites' standard of care"
        }, 
        "brief_title": "Post-Market Surveillance Registry to Monitor Performance and Safety of V8 Device", 
        "condition": "Aortic Valve Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "detailed_description": {
            "textblock": "The study is an open-label observational study involving a minimum of 10 centers.  A minimum\n      of 100 patients, including a minimum of 30 stand-alone balloon aortic valvuloplasty (BAV)\n      treatment patients, will be enrolled.  Enrollment will continue until all 3 of these\n      conditions are met.\n\n      BAV-only patients will be followed through a 6-month post-treatment telephone follow up.\n      Patients treated with the V8 device for BAV as a bridge to transcatheter aortic valve\n      replacement (TAVR) or surgical aortic valve replacement (SAVR) or as an intraprocedural\n      predilatation prior to TAVR, will exit the study at the time of the TAVR or SAVR implant or\n      at 6 months post-BAV treatment, whichever comes first."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic severe aortic stenosis (AS) patients who are not suitable candidates for\n             aortic valve replacement surgery at the time of BAV procedure.\n\n          -  Subject meets the Indication For Use.\n\n          -  Probable survival to hospital discharge.\n\n          -  Subject is competent, willing to comply with evaluations, understands risks, benefits\n             and alternatives and has signed the Informed Consent Form. Alternatively, the legal\n             guardian of the patient is able to give consent to participate.\n\n        Exclusion Criteria:\n\n          -  Patient has undergone previous AVR\n\n          -  Greater or equal to 3+ aortic insufficiency by echocardiogram obtained prior to\n             planned BAV or intra-procedural predilation TAVR procedure\n\n          -  Non-valvular AS\n\n          -  Known congenital AV abnormality (e.g., bicuspid AV)\n\n          -  Cardiogenic shock, as defined by a consistent systolic blood pressure <80 mmHg off\n             vasopressors or <90 mmHg on vasopressors.\n\n          -  Bacterial endocarditis \u2264 12 months prior to planned BAV procedure\n\n          -  Unable to take aspirin (acetyl salicylic acid, ASA) or thienopyridine\n\n          -  Any illness or condition which, in the Investigator's judgment, will compromise\n             patient safety, or interfere with the interpretation of the treatment results\n\n          -  Echocardiographic evidence of intracardiac mass, thrombus or vegetation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic - Patients at each enrolling clinic who are to be treated with the\n        InterValve V8 device for balloon aortic valvuloplasty (BAV) are eligible for enrollment."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099942", 
            "org_study_id": "1058-001"
        }, 
        "intervention": {
            "description": "The V8 device can be used for BAV as follows:\nas stand-alone intervention\nas a bridge to transcatheter aortic valve replacement (TAVR)\nas a bridge to surgical aortic valve replacement (SAVR)\nas an intraprocedural predilatation prior to TAVR", 
            "intervention_name": "V8 Balloon Aortic Valvuloplasty (BAV) Catheter", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Balloon Aortic Valvuloplasty", 
            "Valvuloplasty", 
            "Transcatheter Aortic Valve Replacement", 
            "Surgical Aortic Valve Replacement"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Brenda.Rivers@med.usc.edu", 
                    "last_name": "Rene Rivers, unk", 
                    "phone": "323-422-6192"
                }, 
                "contact_backup": {
                    "email": "christine.tam@med.usc.edu", 
                    "last_name": "Christine Tam, RN, MS, CCRP", 
                    "phone": "(310) 237-3119"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern Califormia"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "melissa.buescher@allina.com", 
                    "last_name": "Melissa Buescher, MPH", 
                    "phone": "612-863-5507"
                }, 
                "contact_backup": {
                    "email": "lisa.tindell@allina.com", 
                    "last_name": "Lisa Tindell, BSN", 
                    "phone": "(612) 863-3816"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55407"
                    }, 
                    "name": "Abbott Northwestern Hospital (with Minneapolis Heart Institute Foundation)"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Transluminal Aortic Balloon Valvuloplasty Registry (TAB-R)", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Successful balloon fixation:  proximal and distal balloon segments are securely fixed on either side of the aortic valve annulus following inflation.", 
                "measure": "Efficacy Endpoint: V8 Device Performance", 
                "safety_issue": "No", 
                "time_frame": "Intra-procedure"
            }, 
            {
                "description": "The composite of SAEs as defined by the Valve Academic Research Consortium (VARC).", 
                "measure": "Safety Endpoint: Serious Adverse Events (SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "Intra-procedure until discharge or 72 hours post-procedure, whichever comes first. (Typical discharge is expected to be within 72 hours.)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099942"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Absolute and percent change in mean aortic valve (AV) gradient and aortic valve area (AVA).", 
                "measure": "Efficacy Endpoint: Intra-Procedure Hemodynamic Changes", 
                "safety_issue": "No", 
                "time_frame": "Intra-procedure"
            }, 
            {
                "description": "Absolute and percent change in mean aortic valve (AV) gradient and aortic valve area (AVA).", 
                "measure": "Efficacy Endpoint: Post-Procedure Hemodynamic Changes", 
                "safety_issue": "No", 
                "time_frame": "Within 72 hours of procedure or discharge, whichever is first.  (Typical discharge is expected to be within 72 hours.)"
            }, 
            {
                "measure": "Safety Endpoint: Aortic Valve (AV) Block at Discharge", 
                "safety_issue": "Yes", 
                "time_frame": "At discharge, which is expected to be within 72 hours procedure."
            }, 
            {
                "measure": "Safety Endpoint: Aortic Valve (AV) Block at 6-Month Follow-up", 
                "safety_issue": "Yes", 
                "time_frame": "6-Month Follow-up"
            }
        ], 
        "source": "InterValve, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InterValve, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "6 Months", 
        "verification_date": "March 2014"
    }
}